Publications by authors named "Marc Garnick"
Introduction: Risk of cardiovascular disease is higher among men with prostate cancer than men without, and prostate cancer treatments (especially those that are hormonally based) are associated with increased cardiovascular risk.
Materials And Methods: An 11-member panel of urologic, medical, and radiation oncologists (along with a men's health specialist and an endocrinologist/preventive cardiologist) met to discuss current practices and challenges in the management of cardiovascular risk in prostate cancer patients who are taking androgen deprivation therapies (ADT) including LHRH analogues, alone and in combination with androgen-targeted therapies (ATTs).
Results: The panel developed an assessment algorithm to categorize patients by risk and deploy a risk-adapted management strategy, in collaboration with other healthcare providers (the patient's healthcare "village"), with the goal of preventing as well as reducing cardiovascular events.
Article Synopsis
- The Prostate Cancer 360 (PC360) Working Group created recommendations to improve patient care during androgen deprivation therapy (ADT) by addressing potential adverse effects.
- The working group, made up of 14 experts in prostate cancer, identified challenges in managing ADT side effects and developed practical care strategies for prescribers.
- The recommendations emphasize a team-based approach involving patients and healthcare providers, focusing on comprehensive education and lifestyle interventions to enhance quality of life and reduce complications associated with ADT.
Purpose: Luteinizing hormone-releasing hormone (LHRH) agonists are believed to have higher cardiovascular risk relative to gonadotropin-releasing hormone (GnRH) antagonists. However, previous studies have not consistently demonstrated this. We used real-world clinical practice data to evaluate differences in major adverse cardiovascular events (MACE) risk between LHRH agonists compared to a GnRH antagonist following androgen deprivation therapy (ADT) initiation.
View Article and Find Full Text PDFArticle Synopsis
- Researchers want to improve how we understand and categorize prostate cancer so doctors can make better treatment decisions.
- They found that new imaging technologies, like PET scans, are helpful in figuring out the stage of cancer and which treatments to use.
- It's crucial to use clear terms to describe prostate cancer stages, so both doctors and patients understand what needs to be done for treatment.
Purpose: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services.
Methods: A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework.
Article Synopsis
- Scientists wanted to see how a hormone called follicle-stimulating hormone (FSH) affects men with prostate cancer who are receiving treatment that lowers male hormones.
- They held a meeting with experts and looked through many research articles to understand how FSH might cause issues like heart disease, weight problems, and weaker bones.
- Findings showed that FSH could lead to health problems when men are treated for prostate cancer, but more research is needed to fully understand how it affects their overall health.
To review current prostate-specific antigen (PSA) metrics used in monitoring treatment of advanced prostate cancer, with a specific focus on castration-resistant prostate cancer (CRPC) therapies. Explore what is known about the correlation between PSA and androgen levels as well as underlying reasons for persistent PSA expression and serum elevation in CRPC, and outline suggestions for use of PSA in managing patients with advanced prostate cancer. A comprehensive search of the PubMed database for English language articles through April 2012 was performed using the following Medical Subject Headings (MeSH) keywords or terms, alone or in combination: 'prostate cancer'; 'prostate cancer treatment'; 'prostate cancer outcomes'; 'prostate-specific antigen'; 'androgen receptor'; 'advanced prostate cancer'; 'castration-resistant prostate cancer'; 'biomarkers'.
View Article and Find Full Text PDF